Most recent update: Friday, April 3, 2020 - 08:40

Bariatric News - Cookies & privacy policy

You are here


EndoBarrier shows reduction in cardio risk

Pooled analysis from two studies shows significant reduction in ten-year cardiovascular risk

New data demonstrating clinically meaningful improvements in the prevalence of metabolic syndrome, as well as a reduction in ten-year cardiovascular risk in obese patients treated with EndoBarrier Therapy, has been presented at the  50th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.

“The findings from our pooled analysis demonstrated that EndoBarrier Therapy for obese patients with and without diabetes, resulted in significant improvements in body weight, glycaemic control and multiple cardiometabolic risk factors, which translated to a consistent reduction in the patients’ ten-year estimated CV risk, using three well-known CV risk models,” said Dr Robert J Chilton, professor, Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, TX. “While further exploration is warranted, EndoBarrier Therapy appears to be an effective tool to rapidly improve a patient’s cardiometabolic health, offering clinicians an adjunctive approach to currently available pharmacotherapy and an alternative to existing surgical options.”

The findings were from two clinical studies of EndoBarrier involving a total of 40 obese patients with and without type 2 diabetes who completed 12 months of treatment with EndoBarrier Therapy.

The results showed that during treatment, the overall cohort lost an average of 18.6% in total body weight and 17.7cm from the waist. Additionally, systolic blood pressure dropped by 7.6mmHg, LDL-cholesterol decreased by 0.6mmol/L, and HbA1c levels were reduced by an average of 2.1% in the diabetic subgroup (n=20).

Given these improvements, the number of patients who met the criteria for metabolic syndrome at the time of EndoBarrier implant (35/40) was reduced by 37% (20/40). Importantly, the use of EndoBarrier Therapy also resulted in a 19- 40% reduction in ten-year cardiovascular risk level, as calculated by three different cardiovascular risk models.

In addition, four other scientific posters highlighting EndoBarrier Therapy were presented during EASD, including data from Dr Andrew Young, vice president, head of Endocrine Biology, GlaxoSmithKline. These findings, which build on earlier data presented at Digestive Disease Week 2014, demonstrate that implantation of the EndoBarrier device in morbidly obese patients with and without type 2 diabetes resulted in increased circulating bile acids, similar to the increase observed in gastric bypass procedures. Such findings may provide some hypothesis as to the EndoBarrier’s potential mechanism of action.

“Type 2 diabetes and obesity pose a growing challenge in clinical practice, and we believe EndoBarrier Therapy represents an important advancement in addressing these dual epidemics,” said Dr David Maggs, chief medical officer of GI Dynamics. “The body of evidence supporting the use of EndoBarrier Therapy continues to grow, not only for its ability to improve type 2 diabetes and obesity, but also for its impact on overall cardiometabolic health.”

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.

EndoBarrier Gastrointestinal Liner

3 years 4 months ago
4 years 3 weeks ago
4 years 6 months ago
4 years 8 months ago
4 years 9 months ago
4 years 10 months ago
5 years 1 month ago
5 years 4 months ago
5 years 6 months ago
5 years 6 months ago
6 years 9 hours ago
6 years 1 week ago
6 years 2 months ago
6 years 4 months ago
6 years 6 months ago
6 years 8 months ago
6 years 9 months ago
6 years 9 months ago
6 years 9 months ago
6 years 10 months ago
7 years 2 months ago
7 years 5 months ago
7 years 5 months ago
7 years 7 months ago
7 years 9 months ago
8 years 8 months ago
9 years 2 months ago